Latent Mycobacterium tuberculosis Enfeksiyonun Tedavisinde Haftalık İsoniazid-Rifapentin Rejiminin Kullanılmasına İlişkin Önerilerin Güncellemeleri

Kaynakça (10)

1. CDC. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis in-fection. MMWR Morb Mortal Wkly Rep 2011;60:1650-3
2. Briss PA, Zaza S, Pappaioanou M, Wright-De Agüero L, Truman BI, Hop-kins DP, et al; The Task Force on Community Preventive Services. Devel-oping an evidence-based Guide to Community Preventive Services—methods. Am J Prev Med 2000;18(Suppl):S35-43
3. Zaza S, Wright-De Agüero LK, Briss PA, Truman BI, Hopkins DP, Hen-nessy MH, et al; Task Force on Community Preventive Services. Data col-lection instrument and procedure for systematic reviews in the Guide to Community Preventive Services. Am J Prev Med 2000;18(Suppl):44-7
4. Njie GJ, Morris SB, Woodruff RY, Moro RN, Vernon AA, Borisov AS. Iso-niazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis. Am J Prev Med 2018. Epub June 11, 2018
5. Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, et al; Inter-national Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr 2015;169:247-55
6. Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, et al; Tu-berculosis Trials Consortium; AIDS Clinical Trials Group for the PREVENT TB Trial. Three months of weekly rifapentine and isoniazid for treat-ment of Mycobacterium tuberculosis infection in HIV-coinfected per-sons. AIDS 2016;30:1607-15
7. Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JA, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother 2014;69:1079-85
8. Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, et al; AIDS Clinical Trials Group A5279 Study Team. Efavirenz pharma-cokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis 2015;61:1322-7
9. Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, et al; TB Trials Consortium iAdhere Study Team. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med 2017;167:689-97
10. Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, et al; Tuberculosis T